Information for Healthcare Providers on Obtaining and Using TPOXX (Tecovirimat) for Treatment of Monkeypox

CDC, in partnership with FDA, has made it easier for healthcare providers to provide tecovirimat (TPOXX) treatment to patients with monkeypox under the Expanded Access Investigational New Drug (EA-IND).

The streamlined process allows healthcare providers to start treatment before the paperwork is submitted, and reduces the number of required forms, patient samples, photos, and gives patients the option to see their doctor virtually.

How to obtain TPOXX

  • TPOXX is available through the Strategic National Stockpile, and multiple state health and territorial departments are pre-positioning supplies of TPOXX within their jurisdictions. Clinicians and care facility pharmacists requesting TPOXX should contact their state/territorial health department. Pre-positioned supply may be the fastest route to obtain TPOXX.
  • For urgent clinical situations after hours, providers may contact the CDC Emergency Operations Center (770-488-7100) for clinical consultation on patient cases.
  • Treatment with TPOXX can begin upon receipt of the medication and after obtaining informed consent.
  • Forms requested under the EA-IND can all be returned to CDC after treatment begins.

Protocol

  • CDC holds an Expanded Access Investigational New Drug (EA-IND) protocol [681 KB, 21 pages] to allow access to and use of TPOXX for treatment of non-variola orthopoxvirus infections, including monkeypox, in adults and children. The EA-IND provides an umbrella regulatory coverage so that clinicians and facilities do not need to request and obtain their own INDs. The EA-IND also provides liability coverage under the PREP Act for compensation to patients if seriously injured via the Countermeasures Injury Compensation Program (CICP).
  • On July 21, 2022, CDC IRB approved the protocol amendment [123 KB, 1 page]; continuation was approved on July 20 [105 KB, 1 page].
  • Clinicians, care facilities, and hospitals providing TPOXX can immediately transition to the revised protocol and forms. Healthcare providers should complete the following forms:

Required

  1. Informed Consent Form English [261 KB, 5 pages] | Spanish [335 KB, 6 pages]: Obtain prior to treatment.
  2. Patient Intake Form [321 KB, 3 pages]: Baseline assessment.
  3. FDA Form 1572 [1 MB, 2 pages]: One signed 1572 per facility suffices for all TPOXX treatments administered under the EA-IND at the same facility.
  4. Clinical Outcome Form [279 KB, 4 pages]: Progress information during and post treatment.
  5. Serious Adverse Events : Report life-threatening or serious adverse events associated with TPOXX by completing a PDF MedWatch Form [956 KB, 5 pages] and returning it to CDC via email (regaffairs@cdc.gov) or uploading to ShareFile within 72 hours of awareness or sooner, if possible. The PDF MedWatch Form can also be downloaded from the FDA website. (Note: The MedWatch Form can only be viewed on the Adobe desktop app. Please save or download the form for viewing.)

Optional Photos and Samples

  • Photos of lesions: If feasible, take lesion photos at baseline prior to TPOXX treatment, and post-treatment to follow lesion progression and healing during treatment.
  • Lesions samples for resistance testing: Ideally, a sample from at least 1 lesion prior to TPOXX treatment but only if baseline diagnostic testing wasn’t performed, as well as samples from any new lesions that develop during and after TPOXX treatment to assess for development of antiviral resistance mutations. Optional Lesion Samples for Resistance Testing [117 KB, 1 page] for instructions on collection, storage, and submission of samples.
  • Pharmacokinetic samples for testing: During TPOXX treatment, plasma samples may be collected to monitor TPOXX levels for adequate drug exposure in patients. Optional Pharmacokinetic Samples for Testing [253 KB, 5 pages] for instructions on collection, storage, and submission of samples.

Optional Patient Diary and Instructions

Institutional Review Board (IRB) Approval

  • CDC IRB serves as the central IRB for review and approval. Facilities may elect to rely on the CDC IRB for centralized review and approval by submitting a request to the CDC’s Human Research Protection Office within 7 calendar days of tecovirimat treatment at your facility. CDC will promptly document an agreement in writing using the CDC IRB Authorization Agreement (Sample Template) [1 MB, 2 pages] which must be signed by both parties.
  • Facilities that elect to obtain their own IRB review must ensure compliance with applicable FDA regulations related to the TPOXX EA-IND protocol. Note that the posted TPOXX EA-IND protocol and the attachments must be used without any changes being made by the IRB.
  • Since this TPOXX EA-IND protocol is solely for treatment use, CDC determined that its use does not constitute research involving human subjects as defined by 45 CFR 46.102, therefore, the federal-wide assurance requirements do not apply.